(Press-News.org) BOSTON (June 4) − A study published in today's New England Journal of Medicine reports that the antibiotic dalbavancin is as effective as vancomycin, the current standard-of-care antibiotic used to treat serious bacterial skin and skin-structure infections. The study results establish dalbavancin as a therapy for Staphylococcus aureus infections, including methicillin-resistant S. aureus, or MRSA. Acute bacterial skin and skin-structure infections are among the most common reasons for the hospitalization of adults in the United States today, and the associated medical costs are substantial.
A team led by Helen Boucher, M.D., Associate Professor of Medicine at Tufts Medical Center, reports the results in an article titled "Once-weekly Dalbavancin versus daily conventional therapy for skin infections."
"Dalbavancin has a great likelihood of changing our practice in caring for patients with severe skin infections. It will now be possible to treat once a week instead of several times a day and will potentially remove the need for hospital admission and long-term intravenous catheters," Boucher said.
The team completed two clinical trials comparing efficacy of dalbavancin with vancomycin followed by linezolid. The Phase 3 studies, called non-inferiority trials, were conducted between 2011-2012. Titled DISCOVER 1 and DISCOVER 2 (Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response), the studies were conducted at 54 and 86 investigative sites, respectively, and were randomized, double-blind, double-dummy trials. (To insure against bias, double-dummy trials include two placebo arms when the study drugs are administered by different methods, for example, orally versus intravenously.)
For the trial, the diagnosis of acute bacterial skin and skin-structure infection required the presence of cellulitis, a major abscess or a wound infection, all with at least 75 square centimeters of surrounding redness. Additional criteria were elevated body temperature and white blood cell count.
For a period of 10-14 days, patients were given either once-weekly intravenous dalbavancin or twice-daily intravenous vancomycin followed by oral linezolid, along with dummy infusions or pills. The primary endpoint was early clinical response, defined as cessation of spread of infection-related reddening and inflammation of the skin and the absence of fever at 48 to 72 hours. Secondary endpoints measured at the conclusion of therapy included clinical status and investigator's assessment of outcome.
Data from the two DISCOVER trials were pooled. Analysis showed that 525 of 659 (79.7 percent) in the dalbavancin group and 521 of 653 (79.8 percent) in the vancomycin-linezolid group had an early clinical response, indicative of treatment success. For patients infected with Staphylococcus aureus, including MRSA, clinical success was seen in 90.6 percent of the dalbavancin-treated patients and 93.8 percent of those treated with vancomycin-linezolid.
Dr. Boucher explained, "The patients in our study were very ill: more than 85 percent had fever at entry and more than half had systemic inflammatory response syndrome. In addition, our patients had large infections with median areas of over 300 square centimeters. Our results establish dalbavancin as an effective therapy and prove non-inferiority of dalbavancin to vancomycin in the treatment of these serious infections."
In 2011, the Centers for Disease Control and Prevention identified antimicrobial resistance as a serious United States and global health concern. The DISCOVER trials were conducted with the help of the Generating Antibiotic Incentives Now (GAIN) provision of the 2012 Food and Drug Administration Safety and Innovation Act to stimulate development of new antibiotics to treat infections. Under the GAIN provisions, these drugs receive a priority review status and undergo an expedited regulatory approval process with FDA.
INFORMATION:
The trials were sponsored by Durata Therapeutics.
Additional authors of the study are Mark Wilcox, M.D., of the University of Leeds, United Kingdom; George H. Talbot of Talbot Advisors in Anna Maria, Florida; Sailaja Puttagunta, M.D., and Michael W. Dunne, M.D., of Durata Therapeutics, Branford, Connecticut; and Anita F. Das, Ph.D., of InClin in San Mateo, Calif.
About Tufts Medical Center
Tufts Medical Center is an exceptional, not-for-profit, 415-bed academic medical center that is home to both a full-service hospital for adults and Floating Hospital for Children. Conveniently located in downtown Boston, the Medical Center is the principal teaching hospital for Tufts University School of Medicine. Floating Hospital for Children is the full-service children's hospital of Tufts Medical Center and the principal pediatric teaching hospital of Tufts University School of Medicine. Tufts Medical Center is affiliated with the New England Quality Care Alliance, a network of nearly 1,800 physicians throughout Eastern Massachusetts. For more information, please visit http://www.tuftsmedicalcenter.org.
New antibiotic proven effective to treat acute bacterial skin infections
Clinical trial shows dalbavancin is as effective as vancomycin
2014-06-05
ELSE PRESS RELEASES FROM THIS DATE:
Mechanism of cell death unraveled -- perspectives for treating inflammatory diseases
2014-06-05
Researchers at VIB and Ghent University have unraveled the mechanism of necroptosis. This is a type of cell death that plays a crucial role in numerous diseases, from viral infections and loss of auditory nerve cells to multiple sclerosis, acute heart failure and organ transplantation. Having detailed knowledge of the cell death process enables a targeted search for new drugs.
Peter Vandenabeele (VIB/UGent): "The molecular mechanism of necroptosis was a complete mystery for a long time. Cells explode. But exactly how they do this was unclear. Now we have found that cells ...
Brain protein may explain depression in pre-menopausal women
2014-06-04
June 4, 2014 (Toronto) – Women nearing menopause have higher levels of a brain protein linked to depression than both younger and menopausal women, a new study by the Centre for Addiction and Mental Health (CAMH) shows.
This finding may explain the high rates of first-time depression seen among women in this transitional stage of life, known as perimenopause.
"This is the first time that a biological change in the brain has been identified in perimenopause which is also associated with clinical depression," says Senior Scientist Dr. Jeffrey Meyer of CAMH's Campbell ...
Weight gain following antidepressant use examined
2014-06-04
Bottom Line: Modest differences exist between antidepressants with regard to weight gain among patients.
Authors: Sarah R. Blumenthal, B.S., Massachusetts General Hospital, Boston, and colleagues.
Background: Previous work has suggested an association between antidepressant use and weight gain. The potential health consequences could be significant because more than 10 percent of Americans are prescribed an antidepressant at any given time. Obesity is associated with a host of medical conditions, including cardiovascular disease, type 2 diabetes and high blood pressure. ...
Deppression with atypical features associated with obesity
2014-06-04
Bottom Line: Major depressive disorder (MDD) with atypical features (including mood reactivity where people can feel better when positive things happen in life, increased appetite or weight gain) appears to be associated with obesity.
Authors: Aurélie M. Lasserre, M.D., of Lausanne University Hospital, Switzerland, and colleagues.
Background: MDD has tremendous public health impact worldwide. Obesity is another burden for public health. Understanding the mechanisms underlying the association between MDD and obesity is important.
How the Study Was Conducted: The ...
Two JAMA Surgery studies examine bariatric surgery for type 2 diabetes treatment
2014-06-04
Bottom Line: Roux-en-Y gastric bypass surgery resulted in the greatest average weight and appears to be the best treatment for type 2 diabetes mellitus (T2DM) compared to gastric banding and lifestyle intervention in a clinical trial that also highlights the challenges to completing a larger trial with patients with a body mass index (BMI) of 30 to 40.
Author: Anita P. Courcoulas, M.D., M.P.H., of the University of Pittsburgh Medical Center, and colleagues.
Background: Questions remain unanswered about the role of bariatric surgery in the treatment of T2DM, including ...
Sea star disease epidemic surges in Oregon, local extinctions expected
2014-06-04
CORVALLIS, Ore. – Just in the past two weeks, the incidence of sea star wasting syndrome has exploded along the Oregon Coast and created an epidemic of historic magnitude, one that threatens to decimate Oregon's entire population of purple ochre sea stars.
Prior to this, Oregon had been the only part of the West Coast that had been largely spared this devastating disease.
The ochre sea star, which is the species most heavily affected by the disease in the intertidal zone, may be headed toward localized extinction in Oregon, according to researchers at Oregon State University ...
Are squiggly lines the future of password security?
2014-06-04
VIDEO:
As more people use smart phones or tablets to pay bills, make purchases, store personal information and even control access to their houses, the need for robust password security has...
Click here for more information.
As more people use smart phones or tablets to pay bills, make purchases, store personal information and even control access to their houses, the need for robust password security has become more critical than ever.
A new Rutgers University study shows that ...
Disinfection caps successful in CLABSI prevention
2014-06-04
Thanks to the simple use of an alcohol-impregnated cap, Loyola University Medical Center achieved a 68 percent decrease in the overall number of central line-associated bloodstream infections (CLABSI) over a 12-month period. A two-year study compared the use of disinfection caps to an intense scrub-the-hub intervention to standard care. Scrub-the-hub refers to cleaning catheter connector hubs and injection ports with alcohol for the recommended 15 seconds before accessing the central line, a catheter placed in a large vein to deliver medicine and liquids during hospitalization. ...
Genetics provide blueprint for new heart disease therapies
2014-06-04
PHILADELPHIA — Advances in the understanding of the genetics of coronary artery disease, or CAD, will revitalize the field and lead to more therapeutic targets for new medicines to combat this common disease, suggests a genetics expert from the Perelman School of Medicine at the University of Pennsylvania in a Perspective article in the new issue of Science Translational Medicine.
Daniel J. Rader, MD, chair of the Department of Genetics and associate director of the Institute for Translational Medicine and Therapeutics, asserts that the lagging search for new heart medicines ...
UCLA researchers identify new gene involved in Parkinson's disease
2014-06-04
A team of UCLA researchers has identified a new gene involved in Parkinson's disease, a finding that may one day provide a target for a new drug to prevent and potentially even cure the debilitating neurological disorder.
Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease, and there is no cure for the progressive and devastating illness. About 60,000 Americans are diagnosed with Parkinson's disease each year. It is estimated that as many as 1 million Americans live with Parkinson's disease, which is more than the number ...
LAST 30 PRESS RELEASES:
Researchers develop an innovative method for large-scale analysis of metabolites in biological samples
Asteroid Bennu is a time capsule of materials bearing witness to its origin and transformation over billions of years
New AI model can help extend life and increase safety of electric vehicle batteries
Wildfires can raise local death rate by 67%, shows study on 2023 Hawaiʻi fires
Yogurt and hot spring bathing show a promising combination for gut health
Study explains how lymphoma rewires human genome
New Durham University study counters idea that Jupiter’s mysterious core was formed by a giant impact
Global study shows racialized, Indigenous communities face higher burden of heart disease made worse by data gaps
Hemoglobin reimagined: A breakthrough in brain disease treatment
Fresh twist to mystery of Jupiter's core
Data-driven designs to improve prosthetic legs
Under or over? The twists and turns of genetic research
Moisture changes the rules of atmospheric traffic jams
Stevens INI advances global Alzheimer’s research with support from the Simon family
New laser “comb” can enable rapid identification of chemicals with extreme precision
The “Mississippi Bubble” and the complex history of Haiti
Regular sleep schedule may improve recovery from heart failure, study finds
Wrinkles in atomically thin materials unlock ultraefficient electronics
Brain neurons are responsible for day-to-day control of blood sugar
Moffitt study uncovers new mechanism of immunotherapy resistance
Brain area 46 is at the center of a network for emotion regulation in marmosets
Self-morphing, wing-like feet enhance surface maneuverability of water striders and robots
Zooming in reveals a world of detail: breakthrough method unveils the inner workings of our cells
DNA from extinct hominin may have helped ancient peoples survive in the Americas
UC Irvine-led research team uncovers global wildfire paradox
Extinct human relatives left a genetic gift that helped people thrive in the Americas
Overinflated balloons: study reveals how cellular waste disposal system deals with stress
The rise of plant life changed how rivers move, Stanford study shows
What traits matter when predicting disease emergence in new populations?
Overcoming disordered energy in light-matter interactions
[Press-News.org] New antibiotic proven effective to treat acute bacterial skin infectionsClinical trial shows dalbavancin is as effective as vancomycin